Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus.
We describe a patient with methicillin-resistant Staphylococcus aureus (MRSA) colonizing the pharynx. The MIC of mupirocin was 0.25 microg/ml before treatment and increased after treatment to 8 microg/ml. Using pulsed-field gel electrophoresis, we confirmed that the genotypes of MRSA that colonized the pharynx before and after the use of mupirocin were identical. We measured the delivery of mupirocin to the pharynx in three normal volunteers and two patients. Low concentrations of mupirocin were present in the pharynx in all cases 10 min to 3 days after intranasal application. Our data suggested that low concentrations of the drug in the pharynx after intranasal application of mupirocin ointment might explain the selection of mupirocin resistance in MRSA.
Watanabe
H
H
Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, Japan. h-wata@net.nagasaki-u.ac.jp
Masaki
H
H
Asoh
N
N
Watanabe
K
K
Oishi
K
K
Kobayashi
S
S
Sato
A
A
Sugita
R
R
Nagatake
T
T
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000032:analysis / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D008297:Male; D016106:Methicillin Resistance / Q000235:genetics; D016712:Mupirocin / Q000008:administration & dosage / Q000032:analysis / Q000494:pharmacology*; D010614:Pharynx / Q000737:chemistry* / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D016712:Mupirocin